Summit Therapeutics (SMMT) Reports Q2 Loss of GBP0.07/Share

Summit Therapeutics (NASDAQ: SMMT) reported Q2 EPS of (GBP0.07), versus (GBP0.08) reported last year.

For earnings history and earnings-related data on Summit Therapeutics (SMMT) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• China approves ivonescimab plus chemo for squamous NSCLC
• Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c